Phase I study of weekly albumin-bound paclitaxel (ab-P) plus weekly cetuximab (Cet) plus intensity-modulated radiation therapy (IMRT) in patients with stage III/IVb head and neck squamous cell carcinoma (HNSCC).
Matthew G. Fury
Research Funding - Celgene
Eric Jeffrey Sherman
No relevant relationships to disclose
Shyam S. Rao
No relevant relationships to disclose
Suzanne L. Wolden
No relevant relationships to disclose
Stephanie Smith-Marrone
No relevant relationships to disclose
Kenneth K. Ng
No relevant relationships to disclose
Boris Mueller
No relevant relationships to disclose
Daphna Y. Gelblum
No relevant relationships to disclose
Pinaki R. Dutta
No relevant relationships to disclose
James Lee
No relevant relationships to disclose
Ronglai Shen
No relevant relationships to disclose
Sarah Kurz
No relevant relationships to disclose
Nora Katabi
No relevant relationships to disclose
Sofia Haque
No relevant relationships to disclose
Nancy Y. Lee
No relevant relationships to disclose
David G. Pfister
No relevant relationships to disclose